Results 11 to 20 of about 47,434 (363)
Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
Frontiers in Oncology, 2022 Cancer cells release nucleic acids, freely or associated with other structures such as vesicles into body fluids, including blood. Among these nucleic acids, circulating tumor DNA (ctDNA) has emerged as a minimally invasive biomarker for tumor molecular ...Estela Sánchez-Herrero, Estela Sánchez-Herrero, Roberto Serna-Blasco, Lucia Robado de Lope, Víctor González-Rumayor, Atocha Romero, Atocha Romero, Mariano Provencio, Mariano Provencio +8 moredoaj +2 more sourcesPrediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
Nature CommunicationsNo consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification is ...Nicolette M. Fonseca, Corinne Maurice-Dror, Cameron Herberts, Wilson Tu, William Fan, Andrew J. Murtha, Catarina Kollmannsberger, Edmond M. Kwan, Karan Parekh, Elena Schönlau, Cecily Q. Bernales, Gráinne Donnellan, Sarah W. S. Ng, Takayuki Sumiyoshi, Joanna Vergidis, Krista Noonan, Daygen L. Finch, Muhammad Zulfiqar, Stacy Miller, Sunil Parimi, Jean-Michel Lavoie, Edward Hardy, Maryam Soleimani, Lucia Nappi, Bernhard J. Eigl, Christian Kollmannsberger, Sinja Taavitsainen, Matti Nykter, Sofie H. Tolmeijer, Emmy Boerrigter, Niven Mehra, Nielka P. van Erp, Bram De Laere, Johan Lindberg, Henrik Grönberg, Daniel J. Khalaf, Matti Annala, Kim N. Chi, Alexander W. Wyatt +38 moredoaj +2 more sourcesTracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Nature, 2023 Measurements of subclonal expansion of ctDNA in the plasma before surgery may enable the prediction of future metastatic subclones, offering the possibility for early intervention in patients with non-small-cell lung cancer. Circulating tumour DNA (ctDNA)C. Abbosh, A. Frankell, T. Harrison, Judit Kisistók, A. Garnett, L. Johnson, S. Veeriah, M. Moreau, Adrian S. Chesh, T. Chaunzwa, J. Weiss, Morgan R Schroeder, S. Ward, Kristiana Grigoriadis, Aamir Shahpurwalla, K. Litchfield, C. Puttick, D. Biswas, T. Karasaki, James R. M. Black, Carlos Martínez-Ruiz, Maise Al Bakir, O. Pich, T. Watkins, E. Lim, A. Huebner, D. Moore, N. Godin-Heymann, Anne L’hernault, H. Bye, Aaron Odell, Paula Roberts, F. Gomes, Akshay J. Patel, Elizabeth Manzano, C. Hiley, N. Carey, Joan Riley, Danielle Cook, D. Hodgson, D. Stetson, J. Barrett, R. Kortlever, G. Evan, A. Hackshaw, R. Daber, J. Shaw, Hugo J. W. L. Aerts, Abel Licon, Joshua A. Stahl, M. Jamal-Hanjani, Jason F. Amrita Apostolos Azmina Keng Mohamad Mohammed F Lester Bajaj Nakas Sodha-Ramdeen Ang Tufail Chowdh, Jason Lester, A. Bajaj, A. Nakas, Azmina Sodha-Ramdeen, K. Ang, M. Tufail, M. F. Chowdhry, M. Scotland, R. Boyles, S. Rathinam, Claire L Wilson, Domenic Marrone, S. Dulloo, D. Fennell, Gurdeep Matharu, L. Primrose, E. Boleti, Heather Cheyne, Mohammed Khalil, S. Richardson, Tracey Cruickshank, Gillian Price, K. Kerr, S. Benafif, Kayleigh Gilbert, B. Naidu, A. Osman, Christer Lacson, G. Langman, Helen Shackleford, M. Djearaman, S. Kadiri, Gary Middleton, Angela E. Leek, Jack Davies Hodgkinson, Nicola Totten, A. Montero, E. Smith, E. Fontaine, F. Granato, H. Doran, Juliette Novasio, K. Rammohan, L. Joseph, P. Bishop, R. Shah, Stuart Moss, Vijay Joshi, P. Crosbie, Kate Brown, M. Carter, A. Chaturvedi, L. Priest, P. Oliveira, C. Lindsay, F. Blackhall, M. Krebs, Y. Summers, A. Clipson, J. Tugwood, Alastair Kerr, D. Rothwell, E. Kilgour, C. Dive, R. Schwarz, Tom L. Kaufmann, G. Wilson, R. Rosenthal, P. Van Loo, Z. Szallasi, M. Sokač, Roberto Salgado, M. Dióssy, J. Demeulemeester, Abigail Bunkum, A. Stewart, Alastair Magness, A. Rowan, Angeliki Karamani, A. Toncheva, B. Chain, B. Campbell, C. Castignani, Chris Bailey, C. Weeden, Claudia Lee, Corentin Richard, C. Naceur-Lombardelli, D. Pearce, D. Karagianni, D. Levi, Elena Hoxha, E. Larose Cadieux, Emma C Colliver, E. Nye, E. Grönroos, F. Gálvez-Cancino, Foteini Athanasopoulou, F. Gimeno-Valiente, G. Kassiotis, Georgia Stavrou, Gerasimos Mastrokalos, Haoran Zhai, H. Lowe, Ignacio Matos, J. Goldman, J. Reading, Javier Herrero, J. Rane, J. Nicod, J. Lam, J. Hartley, K. Peggs, Katey S. S. Enfield, Kayalvizhi Selvaraju, K. Thol, K. Ng, Kezhong Chen, K. Dijkstra, Krupa Thakkar, L. Ensell, Mansi Shah, Marcos Vasquez, Maria Litovchenko, Mariana Werner Sunderland, M. Hill, M. Dietzen, Michelle M Leung, M. Escudero, Mihaela Angelova, M. Tanić, Monica Sivakumar, N. Kanu, O. Chervova, Olivia Lucas, Othman Al-Sawaf, Paulina Prymas, P. Hobson, Piotr Pawlik, R. Stone, R. Bentham, R. Hynds, R. Vendramin, S. Saghafinia, Saioa López, Samuel Gamble, S. Ung, S. Quezada, Sharon P. Vanloo, S. Zaccaria, S. Hessey, S. Boeing, Stephan Beck, S. Bola, Tamara Denner, T. Marafioti, T. Mourikis, V. Spanswick, Vittorio Barbè, Wei-Ting Lu, William Hill, Wing-Kin Liu, Yin Wu, Yutaka Naito, Zoe Ramsden, C. Veiga, G. Royle, C. Collins-Fekete, F. Fraioli, Paul Ashford, T. Clark, Martin D. Forster, S. Lee, E. Borg, M. Falzon, D. Papadatos-Pastos, James Wilson, T. Ahmad, A. Procter, Asia Ahmed, Magali N. Taylor, A. Nair, David S. Lawrence, D. Patrini, N. Navani, R. Thakrar, S. Janes, Emilie Martinoni Hoogenboom, Fleur Monk, James W. Holding, Junaid Choudhary, Kunal Bhakhri, M. Scarci, M. Hayward, N. Panagiotopoulos, Pat Gorman, Reena Khiroya, R. Stephens, Y. Wong, S. Bandula, A. Sharp, Sean Smith, N. Gower, H. Dhanda, Kitty Chan, Camilla Pilotti, R. Leslie, Anca-Ioana Grapa, Hanyun Zhang, K. AbdulJabbar, Xiaoxi Pan, Yinyin Yuan, David Chuter, M. Mackenzie, S. Chee, A. Alzetani, J. Cave, Lydia Scarlett, J. Richards, Papawadee Ingram, S. Austin, Eric Lim, Paulo De Sousa, S. Jordan, A. Rice, H. Raubenheimer, H. Bhayani, L. Ambrose, A. Devaraj, Hema Chavan, S. Begum, S. Buderi, Daniel Kaniu, Mpho Malima, S. Booth, A. Nicholson, Nádia Fernandes, Pratibha Shah, C. Proli, M. Hewish, S. Danson, M. Shackcloth, Lily Robinson, P. Russell, K. Blyth, C. Dick, J. Le Quesne, A. Kirk, M. Asif, R. Bilancia, N. Kostoulas, Mathew Thomas, Nicolai J. Birkbak, N. Mcgranahan, C. Swanton +306 moresemanticscholar +1 more sourceThe Role of ctDNA in Gastric Cancer
Cancers, 2022 Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision making and therapeutic monitoring. It can provide a less invasive and convenient method to capture the tumoural Justin Mencel, Susanna Slater, Elizabeth Cartwright, Naureen Starling +3 moreopenaire +3 more sourcesctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis
Open Life Sciences, 2023 Cell-free circulating tumor DNA (ctDNA) is synthesized by tumor cells, including metastatic tumors, and circulates in the bloodstream. Evidence suggests that ctDNA is a potential predictive and prognostic biomarker for colorectal cancer (CRC), but its ...Wang Da, Zhao Penglai, Lu Tingting, Ren Jingyao, Zhu Lihui, Han Xiaoyong, Zhang Guangming, Dong Xiaohua, Ma Haizhong, Yu Miao, Cai Hui +10 moredoaj +1 more sourcePhase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
Cancer Biology & Medicine, 2021 Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has been shown to produce an objective response in patients with pretreated mBC. Oral vinorelbine also holds promise as a treatment of choice in patients with mBC. This Anjie Zhu, Peng Yuan, Nanlin Hu, Mingzhou Li, Wenmiao Wang, Xue Wang, Jian Yue, Jiayu Wang, Yang Luo, Fei Ma, Pin Zhang, Qing Li, Binghe Xu, Shanbo Cao, Giuseppe Lippi, Yoichi Naito, Mohammed A. Osman, Gustavo N. Marta, Gianluca Franceschini, Armando Orlandi +19 moredoaj +1 more sourcectDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Nature Network Boston, 2023 In the first stage of the BR.36 adaptive trial in patients with non-small cell lung cancer receiving anti-PD1 immunnotherapy, the primary endpoint of concordance between circulating tumor DNA (ctDNA) molecular response and RECIST response was met.V. Anagnostou, Cheryl Ho, G. Nicholas, R. Juergens, A. Sacher, Andrea S Fung, P. Wheatley-Price, S. Laurie, Benjamin Levy, J. Brahmer, A. Balan, N. Niknafs, Egor Avrutin, Liting Zhu, M. Sausen, P. Bradbury, Jill O'Donnell-Tormey, P. Gaudreau, Keyue Ding, Janet E. Dancey +19 moresemanticscholar +1 more source
